Anna Marie Beckmann, Ph.D.

Executive Vice President, Product Development

Dr. Anna Marie Beckmann leads the Product Development team at AAHI, which includes the GMP operations, Clinical Operations, and Regulatory Affairs teams. She is responsible for guiding products through the transitional phase from preclincial research to evaluation in clinical trials, including directing and managing numerous GLP toxicity studies and providing the necessary documentation to the U.S. Food and Drug Administration for review and approval of human clinical trials that include AAHI's immune-enhancing technologies. The Clinical and Regulatory teams manage INDs for AAHI vaccine candidates and Master Files for AAHI formulations for the scucessful review and clinical evaluation of AAHI technology. She has robust experience working with international regulatory authorities including Brazil, Colombia, Peru, Sudan, India, and South Africa, enabling AAHI to achieve its mission of developing vaccines and immunotherapies for resource-limited areas. In her role, she oversees AAHI's in-house state-of-the-art manufacturing facility that produces cGMP adjuvant formulations and self-amplifying RNA-nanostructured lipid carrier delivery vehicles for Phase 1 and 2 clinical trials. 

Dr. Beckmann is a scientist with more than 30 years of experience in academic, biotechnology, and research institute settings with extensive training in early-stage clinical development of vaccines for infectious diseases and cancer. She recevied her BS in Molecular Biology from Vergreen State College and her PhD in Infectious Diseases from Johns Hopkins University School of Public Health. Her thesis focused on the pathobiology of infection with human polyomaviruses. Dr. Beckmann joined University of Washington as a Senior Fellow in the STD Prevention Training Center and became a faculty member at Red Hutchinson Cancer Research Center, where her research focused on teh pathogenesis of HPV infections and the relation between HPV infections and human anogenital cancers. She then joined Corixa Corporation in 1998 as Director of Regulatory Affairs, which led her to her current role at AAHI managing the clinical development of AAHI's immune-enhancing platform technology. Since joining AAHI, Dr. Beckmann and her teams have successfully managed 18 Phase 1 and 2 clinical trials including adjuvant formulation technology for a variety of disease indications including human immunodeficiency virus (HIV), malaria, tuberculosis, leprosy, leishmaniasis, and schistosomiasis. 

Education

Ph.D., Infectious Diseases, Johns Hopkins University School of Public Health, 

BS, Molecular Biology, Evergreen State College,

Recent Grants and Contracts

Principal Investigator on Bill & Melinda Gates Foundation-funded project to provide GMP material for human clinical trials and maintain clinical readiness of the facility in compliance with FDA regulations (Contract No. OPP1130616).

Co-Principal Investigator on NIH-funded project developing a bivalent RNA-based vaccine targeting yellow fever and Zika viruses (Contract No. 75N93019C00059).

Co-Principal Investigator on NIH-funded project developing a lyophilized, thermostable tuberculosis vaccine candidate (Contract No. HHSN272201400041C).